Okay. My time's running out. I've got your answer and I'm not satisfied. I think we should devote a whole session to receiving your latest report to Parliament on the PMPRB.
I would like to know why you're branching out so extensively into generic drugs. You said yourself you deal with patent medicines. You are now engaged in imposing excessive price guidelines on some generic products. You're using the argument that they may be associated with a patent. There are huge concerns in the community about what's going on.
The generic drugs association has written to the minister saying that you're now asserting that you have jurisdiction over any medicine with a patent, including generic medicines with patents that are sold in competitive multi-sourced environments. And then they say that while it's true that a small minority of generic products are associated with patents through process innovations or licence requirements, no price or market advantage can be obtained by a generic patent.
So I want to know why you're doing this, and why you're not trying to include their voices in the consultations. Is this where some of the money is going? Are you branching out, and do you have the authority under the act--under the Patented Medicines Prices Review Board--to actually do this? Has the minister given her consent to this?